NUS Medicine and research partners to collaborate on prevention and treatment of cardiovascular disease
Published: 10 Dec 2024
On December 6 2024, the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine), Kailuan General Hospital, Tianjin Medical University, and Tianjin Medical University General Hospital signed a Memorandum of Understanding (MOU) at Kailuan General Hospital. This agreement marks a significant step forward in exploring new directions and strategies in the prevention and treatment of cardiovascular disease, opening a new chapter in scientific research collaboration among the four institutions.
The Project RESET Parallel Cohort, spearheaded by Professor Roger Foo, Vice-Dean for Research at NUS Medicine and researcher in cardiovascular diseases, is at the core of this collaboration. Aiming to explore the immune, lipid, and metabolic drivers of cardiovascular disease, Project RESET Parallel Cohort studies data from a diverse Asian, multi-ethnic cohort using cutting-edge multi-omics technology and big data analysis to uncover molecular, metabolic, and immunological markers of heart disease. Additionally, the project will validate the effectiveness of artificial intelligence and digital health interventions through nested randomised controlled trials.
Tianjin Medical University, with its strong academic heritage and expertise in cardiovascular research, will contribute by valuable support to investigate subclinical cardiovascular diseases, an area of growing concern in the Asian population.
Tianjin Medical University General Hospital, a leading tertiary hospital known for its scientific research, medical treatment, and teaching, has a solid foundation for high-end scientific research cooperation.
The partnership will look to fill gaps in the field of subclinical cardiovascular disease research and contribute to the development of precise, personalized prevention and management strategies for cardiovascular conditions. Through this collaboration, the four institutions will create a high-level scientific and technological platform for innovation and talent development, jointly advancing research in subclinical cardiovascular diseases. The MOU will also enable the sharing of knowledge and expertise across disciplines, further enhancing clinical and academic cooperation.
Following the signing ceremony, NUS Medicine provided detailed insights into the specific implementation plans, data collection, and research processes involved in the RESET project. Professor Wu Shouling, the General Director of Kailuan Research at the Kailuan General Hospital, also shared the unique advantages and progress of Kailuan Research, highlighting its pivotal role in this collaboration.
NUS Medicine looks forward to continuing its close cooperation with its partners to contribute to global health advancements.
